Table 2.
Regression Coefficients and Standardized (β) Regression Coefficients From the Fully Adjusted Linear Regression Model Examining the Effects of Baseline FSH on Change in BMD at the Lumbar Spine Over the Ensuing 12 Months in 188 Women Diagnosed With Premenopausal Breast Cancer
| Coefficient | β-Coefficient | SE | P Value | |
|---|---|---|---|---|
| FSH (IU/L) | −0.023 | −0.219 | 0.008 | .007 |
| Age (y) | −0.141 | −0.222 | 0.048 | .004 |
| Baseline LS BMD (g/cm2) | −4.258 | −0.139 | 2.185 | .05 |
| Treatment group (exercise vs control) | 0.867 | 0.126 | 0.490 | .08 |
| Race/ethnicity (White, Black, Asian, Hispanic) | −0.533 | −0.160 | 0.229 | .02 |
| hsCRP (ng/mL) | −0.0001 | −0.174 | 0.0001 | .01 |
| Tamoxifen use (yes/no) | 0.083 | 0.048 | 0.129 | .52 |
| Menstruating (yes/no) | 0.151 | 0.017 | 0.714 | .83 |
| Time from chemotherapy (d) | −0.002 | −0.090 | 0.002 | .20 |
| Estradiol (pg/mL) | −0.004 | −0.101 | 0.003 | .14 |
| lnCTX (ng/mL) | −1.034 | −0.162 | 0.508 | .04 |
BMD, bone mineral density; hsCRP, high sensitivity C reactive protein; lnCTX, serum C-terminal telopeptide (log transformed); LS, lumbar spine.